Vasculitis refers to inflammation of blood vessels.
Vasculitis is a very broad term that in its simplest form refers to inflammation of blood vessels. There are many different causes of vasculitis and they usually present in a myriad of ways. The exact cause of vasculitis is unknown and the underlying mechanisms leading to blood vessel inflammation vary between conditions (e.g. antibody-mediated, T-cell mediated).
There has been a lot of work on classifying vasculitides into different types. They are a very heterogenous group of conditions that can affect multiple organs and in some cases be life-threatening.
Several important terms are used when discussing vasculitides, which may include:
Vasculitis can be broadly divided into primary or secondary:
Blood vessel inflammation may affect multiple organs (i.e. systemic) or be restricted to a single organ (i.e. localised). When vasculitis is localised to single organ it is usually termed single-organ vasculitis (SOV).
SOV classically affects the skin, central nervous system or aorta:
Overtime, SOV may develop into a more systemic vasculitis involving other organs.
Any blood vessel may be affected in vasculitis. These include:
The size of the blood vessel involved forms part of the classification system for primary vasculitis syndromes (discussed further below).
The clinical features of vasculitis depend on both the size of the vessels involved (e.g. large, medium or small) and the location of the vessels involved (e.g. kidney, skin or gut vessels). However, there are certain clinical features that are strongly suggestive of a vasculitic process. These features include:
Classification of the vasculitides is based on the international Chapel Hill Consensus Conference nomenclature.
The international Chapel Hill Consensus Conference helps to classify all types of vasculitides into broad categories and provides useful definitions for each category.
The primary vasculitides are divided based on vessel size (large, medium, small) and the secondary vasculitides are divided into subgroups depending in the suspected aetiology (associated with systemic disease, associated with likely aetiology). SOV is divided into a separate category and for vasculitides that can affect any size vessel the term ‘variable vasculitis’ is used.
The exact cause of vasculitis remains unknown.
There are numerous theories as to why vasculitis develops, which are related to both environmental and genetic factors. However, the exact cause remains unknown. The principal problem is inflammation of blood vessels, which may manifest by several different mechanism that can include:
The exact pathological mechanisms are complex and related to the underlying disease process.
The major consequence of acute or chronic inflammation in blood vessels is that it interrupts blood flow to vital organs. This disruption occurs due to bleeding from damage of the vascular structures or from occlusion as a result of the inflammatory process. In either case, there is ischaemia, tissue damage and ultimately organ dysfunction. This organ dysfunction may occur acutely and can be life-threatening (e.g. gut ischaemia, acute kidney injury).
Giant cell arteritis is a classic cause of large vessel vasculitis.
The two major causes of large vessel vasculitis include:
Giant cell arteritis (GCA), also known as temporal arteritis, is a large vessel vasculitis that predominantly affects the aorta and its branches. It typically occurs in older adults and has a predilection for the branches of the carotid artery. It is characterised by a unilateral headache, scalp pain, and visual loss due to involvement of the ophthalmic artery. It is considered a medical emergency because without prompt recognition and treatment it can lead to permanent visual loss.
For more information see our Giant cell arteritis note.
Takayasu arteritis is a rare type of vasculitis that predominantly affects woman (>80%) and is mainly seen in patients of Asian ethnicity. It predominantly affects the aorta and its major branches leading to features of arterial insufficiency (e.g. weak or absent distal pulses, limb claudication). Diagnosis is usually made on imaging.
Kawasaki disease is a medium vessel vasculitis predominantly found in children.
The two major causes of medium vessel vasculitis include:
Polyarteritis nodosa (PAN) is a rare medium vessel vasculitis that may also affect the small vessels in some cases. It can affect virtually any organ and is slightly more common in males with a peak incidence in the sixth decade of life. The majority of cases are idiopathic but it can be associated with underlying hepatitis B or C infection. PAN characteristically affects the skin (e.g. purpura), kidneys (e.g. acute kidney injury, hypertension), nervous system (e.g. peripheral neuropathy) and causes abdominal pain (due to mesenteric arteritis). On imaging, typical findings in PAN are multiple aneurysms and irregular constrictions of arterial vessels.
This is the most common form of vasculitis in children and leads to widespread involvement of medium-sized vessels. It is typically a self-limiting disease that is diagnosed based on characteristic criteria of fever for ≥ 5 days alongside 4/5 of the following features:
Other features can be present and long-term children may develop cardiovascular complications including coronary artery aneurysms, heart failure, arrhythmias and peripheral arterial disease.
The small vessel vasculitides can be divided based on their association with the autoantibody ANCA.
Vasculitis of the small vessels typically causes inflammation of the small arteries of organs, arterioles, capillaries and venules. They are classically caused by immune-complexes or the autoantibody antineutrophil cytoplasmic antibody (ANCA).
AAV is an umbrella term for three conditions:
These conditions are small vessel vasculitides characterised by a positive ANCA that can affect arterioles, capillaries and venules. While MPA and GPA are similar conditions, EGPA has a different predilection of organ involvement (predominantly ENT, pulmonary and cutaneous involvement) and also affects medium-sized vessels. In AAV, ANCA autoantibodies have characteristic staining patterns and associate with two antigen targets known as myeloperoxidase (MPO) and proteinase 3 (PR3).
For more information see our separate notes (links above)
This refers to small vessel inflammation caused be deposition of immunoglobulins and/or complement. The renal glomeruli are frequently involved in these types of vasculitis. There are four principal causes:
Vasculitis may be associated with an underlying autoimmune disorder, infection or culprit drug.
Connective tissue diseases are commonly associated with vasculitis and can include rheumatoid arthritis, systemic lupus erythematosus, relapsing polychondritis, or sarcoidosis. Treatment is usually targeted at both the underlying disease and the vasculitis with immunosuppressive therapies.
Infections linked with the development of vasculitis may include hepatitis B/C and syphilis. Many drugs can lead to a cutaneous small vessel vasculitis from a type of hypersensitivity reaction (type III) with formation of immune complexes. Common culprit medications include penicillins, cephalosporins, sulfonamides, phenytoin and allopurinol. Rarely, other organs may be involved. Some drugs can even cause an ANCA-associated vasculitis pattern.
In clinical practice, diagnosis of vasculitis can be difficult because of the non-specific presentation.
Vasculitis can present with many non-specific features such as fever, malaise and weight loss. This leads to the investigation of more common diagnoses such as infection or cancer before the diagnosis becomes more apparent or is searched for.
A specific diagnosis of vasculitis is usually reached by a diagnostic criteria depending on the underlying cause. These criteria usually involve a combination of clinical, laboratory, imaging and/or biopsy results.
Certain clinical features may be non-specific in vasculitis (e.g. fever) whereas others are highly suspicious (e.g. palpable purpura). The features supportive of vasculitis include:
Patients with suspected vasculitis usually undergo a ‘vasculitis screen’, which refers to a series of investigations to search for the possible underlying cause of vasculitis. This includes assessing for non-specific markers of an inflammatory process (e.g. CRP, ESR, complement), specific tests for primary vasculitides (e.g. ANCA) and specific tests for secondary vasculitides (e.g. Anti-CCP for rheumatoid).
Typical vasculitis screen
Non-specific features suggestive of vasculitis include low complement levels, raised inflammatory markers, anaemia and/or evidence of organ dysfunction (e.g. acute kidney injury). More specific features include autoantibodies (e.g. positive ANCA or cryoglobulin).
Depending on the type of vasculitis, suspected aetiology and clinical presentation a variety of other investigations can be requested including imaging and some highly specialist tests.
A variety of imaging modalities can be used to detect vascular involvement. This is mainly important for large and medium size vessel vasculitis. Options include MR angiograms, CT angiograms, vascular ultrasound and even positron emission tomography. Rarely, direct angiography may be used via the interventional radiologists to assess for structural vascular abnormalities.
Biopsies may be required depending on the presentation. Examples of when biopsies are used to confirm the diagnosis of vasculitis include:
The treatment of vasculitis typically involves the use of immunosuppressive drugs at high doses.
Immunosuppressive therapies are the principal agents used in the treatment of vasculitis but the choice, dose, route and frequency is guided by the underlying cause and extent of organ involvement. An in-depth analysis of the management of vasculitis is far beyond the scope of these notes.
Corticosteroids (e.g. prednisolone) form the standard medical therapy that are often given at high doses. In severe cases, intravenous methylprednisolone may be required (e.g. GCA with sight-threatening presentation). In small vessel vasculitides, corticosteroids may need to be combined with other immunosuppressive agents such as cyclophosphamide to prevent serious end-organ damage. If end-organ damage does occur, treatment needs to be directed towards this as well (e.g. dialysis in severe acute kidney injury). It is important to think about steroid-related side-effects that are commonly seen in this patient group due to the requirement of often long and protracted courses of steroids. Remember, topics such as steroid side-effects are far more commonly tested at undergraduate level than individual treatment regimens for different vasculitides.
Have comments about these notes? Leave us feedback